Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Douglas Smith

Showing results (31-40 of 203) with videos related to

Pageof 21
Sort By:
Cancer|February 22, 2017
Meaningful endpoints for therapies approved for hematologic malignanciesB Douglas Smith, Amy E DeZern, Alex W Bastian, et al.
Leukemia Research Reports|April 4, 2022
Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysisJose Tinajero, Khaled El-Shami, Xiaojun Wu, et al.
Analytical Biochemistry|January 15, 2005
Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometryMing Zhao, Michelle A Rudek, Ping He, et al.
Experimental Hematology & Oncology|March 27, 2014
Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysisB Douglas Smith, Charles L Beach, Dalia Mahmoud, et al.
Leukemia & Lymphoma|March 4, 2022
Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 studyGuillermo Garcia-Manero, Vincent Ribrag, Yayan Zhang, et al.
Current Medical Research and Opinion|January 9, 2016
Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapyB Douglas Smith, Jun Liu, Dominick Latremouille-Viau, et al.
Leukemia & Lymphoma|September 27, 2021
Infections in secondary immunodeficiency patients treated with Privigen<sup>®</sup> or Hizentra<sup>®</sup>: a retrospective US administrative claims study in patients with hematological malignanciesRajiv Mallick, Victoria Divino, B Douglas Smith, et al.
American Journal of Hematology|June 6, 2014
Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplantSarah L Sammons, Keith W Pratz, B Douglas Smith, et al.
British Journal of Haematology|April 16, 2003
Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiationWilliam Matsui, Carol Ann Huff, Milada Vala, et al.
AJSP: Reviews & Reports|July 14, 2020
B-Lymphoid Blast Phase of Chronic Myeloid Leukemia: A Case Report and Review of the LiteratureAlisha D Ware, Laura Wake, Patrick Brown, et al.
Pageof 21

Showing results (31-40 of 203) with videos related to

Sort By:
Pageof 21
Cancer|February 22, 2017
Meaningful endpoints for therapies approved for hematologic malignanciesB Douglas Smith, Amy E DeZern, Alex W Bastian, et al.
Leukemia Research Reports|April 4, 2022
Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysisJose Tinajero, Khaled El-Shami, Xiaojun Wu, et al.
Analytical Biochemistry|January 15, 2005
Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometryMing Zhao, Michelle A Rudek, Ping He, et al.
Experimental Hematology & Oncology|March 27, 2014
Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysisB Douglas Smith, Charles L Beach, Dalia Mahmoud, et al.
Leukemia & Lymphoma|March 4, 2022
Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 studyGuillermo Garcia-Manero, Vincent Ribrag, Yayan Zhang, et al.
Current Medical Research and Opinion|January 9, 2016
Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapyB Douglas Smith, Jun Liu, Dominick Latremouille-Viau, et al.
Leukemia & Lymphoma|September 27, 2021
Infections in secondary immunodeficiency patients treated with Privigen<sup>®</sup> or Hizentra<sup>®</sup>: a retrospective US administrative claims study in patients with hematological malignanciesRajiv Mallick, Victoria Divino, B Douglas Smith, et al.
American Journal of Hematology|June 6, 2014
Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplantSarah L Sammons, Keith W Pratz, B Douglas Smith, et al.
British Journal of Haematology|April 16, 2003
Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiationWilliam Matsui, Carol Ann Huff, Milada Vala, et al.
AJSP: Reviews & Reports|July 14, 2020
B-Lymphoid Blast Phase of Chronic Myeloid Leukemia: A Case Report and Review of the LiteratureAlisha D Ware, Laura Wake, Patrick Brown, et al.
Pageof 21